Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Improving Your Bottom Line: Mid Year Analysis Vital to Practice
Owen Dahl, Owen Dahl Consulting
FDA Update: Immune Response Robustness Correlates with Survival in Brain Cancer Vaccine Trial
Tracy Hampton, PhD, MDLinx Oncology
  See all
Interferon-beta therapy for malignant melanoma Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Interferon-β therapy for malignant melanoma: The dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells
Archives of Dermatological Research, 05/12/08
Print     Email This Article     Save in My Library   Free Abstract
Kubo H et al. - Direct and indirect inhibitory effects of human interferon-β (HuIFN-β) on human melanoma cells are demonstrated that suggest a need for local higher concentration of HuIFN-β to eradicate melanoma lesions.

Methods
  • Aim was to investigate the anti-tumor effect of HuIFN-β against malignant melanoma
  • In vitro studies were carried out in melanoma cell lines: MM-AN, MM-BP, MM-LH, MM-RU, PM-WK, RPM-EP, RPM-MC
  • For in vivo studies, HuIFN-&beta was administered into cutaneous metastatic lesions of melanoma to evaluate the clinical and histopathological effects

Results
  • In vitro study revealed that HuIFN-&beta not only inhibited proliferation of melanoma cells but also induced apoptosis in a dose dependent fashion
  • The sensitivity to HuIFN-β was different among cell lines
  • Size of the metastatic cutaneous lesion did not change by the intralesional injection of HuIFN-β
  • However, histopathological examination revealed apoptotic changes of melanoma cells along with dense lymphohistiocytic infiltration

 

--- BASIC SCIENCE/GENETICS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

--- DERMATOLOGIC ONCOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

Sponsor
--- PHARMACOLOGY/THERAPY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.